Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

APOMAG-62K

Millipore

MILLIPLEX® Human Apolipoprotein Magnetic Bead Panel - Cardiovascular Disease Multiplex Assay

This Bead-Based Multiplex Assay, using the Luminex® xMAP® technology, enables the simultaneous analysis of Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E.

Synonym(s):

human apolipoprotein CVD immunoassay panel, luminex human apolipoprotein cardiovascular disease multiplex assay, millipore human apolipoprotein CVD multiplex kit

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84
To order a Milliplex® kit, please search for your analyte of interest.
Design And Price Your Kit

feature

This Bead-Based Multiplex Assay, using the Luminex® xMAP® technology, enables the simultaneous analysis of Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E.

Quality Level

200

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 85%
(Apo E)
accuracy: 86%
(Apo AI)
accuracy: 89%
(Apo CIII)
accuracy: 92%
(Apo B)
sensitivity: 1.00 ng/mL
(Apo AII)
sensitivity: 1.22 ng/mL
(Apo CII)
sensitivity: 1.42 ng/mL
(Apo E)
sensitivity: 1.48 ng/mL
(Apo AI)
sensitivity: 1.71 ng/mL
(Apo CIII)
sensitivity: 4.84 ng/mL
(Apo B)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

Metabolic Syndrome has received increased attention from the medical community with increasing cases of obesity, type 2 diabetes and related cardiovascular diseases being described and studied.

MILLIPLEX® Human Apolipoprotein Panel is a 6-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, tissue culture supernatant or other biological samples: APOA-1, APOA-2, APOB, APOC-2, APOC-3, and APOE. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cardiovascular

Specificity

Cross Reactivty
To test cross-reactivity among the assays in the panel, individual apolipoprotein standard was prepared at a concentration 4 times greater than the highest concentration in the calibration curve and tested in the 6-plex assays with multiplexed beads containing immobilized capture antibodies and individual detection antibodies. There was negligible cross-reactivity within the panel.

Application

  • Analytes: Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E
  • Recommended Sample Type: Human serum, plasma, tissue culture supernatant or other biological samples
  • Recommended Sample Dilution: 10 μL of a 1: 4,000 dilution of plasma or serum
  • Assay Run Time: Primary incubation of 1 hour followed by a secondary incubation of 30 minutes, both at room temperature (20-25°C)
  • Research Subcategory: Cardiovascular Disease

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Other Notes

Please contact Technical Service for linearity of dilution.
Standard curve range: Refer to the kit protocol for details.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elise Grytten et al.
Clinical nutrition (Edinburgh, Scotland), 40(5), 2556-2575 (2021-05-03)
Marine-derived omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower circulating levels of triacylglycerols (TAGs), and the plant-derived omega-6 (n-6) PUFA linoleic acid (LA) may reduce cholesterol levels. Clinical studies on effects of these
Consumption of buckwheat modulates the post-prandial response of selected gastrointestinal satiety hormones in individuals with type 2 diabetes mellitus.
Stringer, DM; Taylor, CG; Appah, P; Blewett, H; Zahradka, P
Metabolism, Clinical and Experimental null
Xiaoke Yin et al.
Circulation. Cardiovascular genetics, 10(6) (2017-12-15)
Mass spectrometry is selective and sensitive, permitting routine quantification of multiple plasma proteins. However, commonly used nanoflow liquid chromatography (LC) approaches hamper sample throughput, reproducibility, and robustness. For this reason, most publications using plasma proteomics to date are small in
Ramu Adela et al.
Journal of translational medicine, 17(1), 17-17 (2019-01-25)
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The purpose of the present study was to discriminate the Indian CAD patients with or without T2DM by using multiple
Pierre-François Meyer et al.
Annals of clinical and translational neurology, 6(6), 1127-1133 (2019-06-19)
We studied 78 participants having a parental or multiple-sibling history of Alzheimer's disease (AD) in a two-year randomized placebo-controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100
View All Related Papers

Related Content

Multiplex Measurement of CVD Biomarkers | MILLIPLEX® Assays

Learn about biomarkers of cardiovascular disease (CVD) and discover how multiplex CVD panels, such as MILLIPLEX® multiplex assays, are being used to increase the efficiency of biomarker discovery for CVD research.

Tips & Tricks | Guide to Multiplexing | MILLIPLEX® Assays

Uncover tips and tricks to multiplexing in this guide from the experts. Learn how you can enhance the power of your research with MILLIPLEX® multiplexing, including industry guidance for immunoassays, multiplexing tips, one-day MILLIPLEX® multiplex assays for limited lab time, and more.

Multiplexing Metabolic Syndrome Biomarkers | MILLIPLEX® Assays

Multiplex immunoassays, such as MILLIPLEX® multiplex metabolic assays, are critical in metabolic syndrome research because they provide a full picture of the different conditions related to it, like diabetes and obesity, as well as save time and sample volume.

Questions

  1. Can you provide information on whether Milliplex Human Apolipoprotein Magnetic Bead Panel kit measures a specific type of apolipoprotein proteoform or if it includes measurements for all types of proteoforms? (Cat# APOMAG-62K)

    1 answer

    1. The Milliplex Human Apolipoprotein Magnetic Bead Panel includes the following components:

      - APO AI: It consists of a capture antibody (monoclonal) designed against purified full length human apolipoprotein A1, and a detection antibody (monoclonal) specific to human APO A I, whether purified or in the form of HDL.

      - APO AII: This includes a capture antibody (polyclonal) specific for human apolipoprotein A II, and a detection antibody (polyclonal) also specific to human APO II.

      - APO B: It comprises a capture antibody (monoclonal) specific for native human APO B in the form of LDL, and a detection antibody (monoclonal) specific to human APO B in the form of LDL.

      - APO C II: This involves a capture antibody (polyclonal) specific to human APO CII, with a corresponding detection antibody (polyclonal) specific to human APO C II.

      - APO C III: It contains a capture antibody (polyclonal) specific to human APO CIII, along with a detection antibody (polyclonal) specific to human APO C III.

      - APO E: This component includes a capture antibody (polyclonal) specific to human APO E, and a detection antibody (polyclonal) specific to human APO E.

      Helpful?

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service